Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2017 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G. Loibl S, et al. J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1. J Clin Oncol. 2021. PMID: 33793299 Clinical Trial.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. Shirzadi Z, et al. JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849
TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
Glynn RW, Mahon S, Curran C, Callagy G, Miller N, Kerin MJ. Glynn RW, et al. Oncologist. 2011;16(7):949-55. doi: 10.1634/theoncologist.2011-0071. Epub 2011 Jun 24. Oncologist. 2011. PMID: 21705665 Free PMC article.
RESULTS: Amplification levels of TOP2A did not differ significantly according to HER-2/neu status by either RQ-PCR or IHC microarray. Of the HER-2/neu(-) patients, 29.1% demonstrated levels of TOP2A above the third quartile, whereas 22.9% of the HER-2/neu(+) …
RESULTS: Amplification levels of TOP2A did not differ significantly according to HER-2/neu status by either RQ-PCR or IHC microarray. …
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G. Joh JE, et al. Oncologist. 2011;16(11):1520-6. doi: 10.1634/theoncologist.2011-0045. Epub 2011 Oct 20. Oncologist. 2011. PMID: 22016474 Free PMC article.
RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2% 2.3% of cases. ...
RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estim …
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P. Laurent C, et al. J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1. J Clin Oncol. 2017. PMID: 28459613